Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QZJ
|
|||
| Former ID |
DIB011413
|
|||
| Drug Name |
CC-122
|
|||
| Synonyms |
cc-122; 1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1 | [1] | |
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1 | [1] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [1] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [1], [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [3] | ||
| Company |
Celgene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H14N4O3
|
|||
| Canonical SMILES |
CC1=NC2=CC=CC(=C2C(=O)N1C3CCC(=O)NC3=O)N
|
|||
| InChI |
1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
|
|||
| InChIKey |
RSNPAKAFCAAMBH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1015474-32-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16404595, 17405697, 23480767, 24278716, 42394690, 50107062, 52415579, 53778247, 56463467, 91703265, 92303331, 123100674, 134339796, 135372722, 135698168, 136379554, 152049710, 152212294, 152254728, 152344428, 160840400, 162011471, 163099635, 163565095, 172093635, 172096435, 172870784, 174473416, 180672643, 184594793, 185981674, 204420262, 223378425, 223434978, 233947597, 241181833, 242060373, 249741609, 249847349, 250179619, 250201211, 252033978, 252215065, 252315895, 252430933
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein cereblon (CRBN) | Target Info | Modulator | [2], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01421524) Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 4 | CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015 Aug 6;126(6):779-89. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.